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Abstract The ob gene product, leptin, causes significant and
dose-dependent inhibition of basal and insulin-stimulated glyco-
gen synthesis in isolated soleus muscle from ob/ob mice, and a
smaller, non-significant inhibition in muscle from wild-type mice.
Leptin had no inhibitory effect on glycogen synthesis in soleus
muscle from the diabetic (db/db) mice, which lack the functional
leptin receptor. The full-length leptin receptor (Ob-Rb), is
expressed in soleus muscle of both ob/ob and wild-type mice,
however with no detectable differences in expression level. These
results suggest that hyperleptinaemia may attenuate insulin
action on glucose storage in skeletal muscle.
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1. Introduction
Leptin, encoded by the ob gene, is produced exclusively by
adipocytes. Reduction in the production of leptin or the sen-
sitivity to leptin in rodents results in a phenotype of obesity
and diabetes. Thus, leptin de¢ciency in the ob/ob mouse [1] or
the lack of a functional leptin receptor (Ob-Rb) in the diabetic
(db/db) mouse [2] or Zucker fa/fa rat [3] leads to obesity,
hyperglycaemia and insulin resistance, resembling non-insulin
dependent diabetes mellitus (NIDDM) in humans. Adminis-
tration of leptin into ob/ob mice causes a signi¢cant reduction
of food intake and body weight as well as normalization of
the metabolic status, but has no e¡ects in the db/db mice [4^6].
However, the mutations responsible for the ob/ob, db/db and
fa/fa phenotypes in rodents have not been detected in obese
humans. In fact, plasma leptin levels in obese humans are
elevated and there is a positive correlation with body mass
index, thus arguing against a simple leptin de¢ciency as the
cause of human obesity [7,8]. These ¢ndings have led to the
suggestion that leptin resistance may be part of the patho-
genesis of human obesity.
The leptin receptor (Ob-R) is expressed as alternatively
spliced variants [2]. Only the Ob-Rb isoform, predominantly
expressed in hypothalamus, contains the full-length cytoplas-
mic domain and is believed to be the functional receptor. A
point mutation within the Ob-R gene of db/db mice results in
the lack of the cytoplasmic domain that is thought to interact
with the Jak/STAT pathway and is therefore unable to medi-
ate a functional leptin signal [3,9,10]. Ob-Rb mRNA expres-
sion has also been detected in peripheral tissues such as pan-
creatic islets, liver, kidney and lung [2,11,12], indicating that
leptin may have other physiological functions in addition to
regulating feeding behaviour. In fact, we have demonstrated
that leptin can inhibit insulin secretion from pancreatic islets
[12], and Levin et al. [13] have shown that infusion of leptin
into ob/ob mice causes depletion of their liver glycogen con-
tent as well as a reduction in the plasma concentrations of
glucose, insulin and cholesterol.
Skeletal muscle is the major site of insulin mediate glucose
storage. The aim of the present study was to investigate for
the ¢rst time the e¡ects of leptin on skeletal muscle glucose
metabolism.
2. Materials and methods
2.1. Animals
Female ob/ob mice and wild-type (+/+) mice of the Aston strain
were bred in our laboratory. The db/db mice were obtained from
Harlan-Olac (Bicester, Bucks, UK). Animals were housed on a 12
h : 12 h dark cycle (08:00^20:00 h) with free access to water and
standard laboratory chow (Beekay rat and mouse toxicology diet,
Bantin and Kingman, Hull, UK).
2.2. Measurement of glycogen synthesis in isolated soleus muscle
Non-fasted mice were killed by cervical dislocation. Intact soleus
muscles weighing 4^6 mg were dissected and tendons were tied onto a
stainless steel clip under slight tension to maintain each muscle at
resting length. The muscles were immediately placed in individual
£asks containing 3 ml of Krebs-Ringer bicarbonate (KRB) bu¡er
with 5.5 mM glucose, 0.14% bovine serum albumin and 10 mM




(pH 7.4). All £asks
were immediately sealed and transferred to a shaking water bath





min pre-incubation, the muscles were transferred to fresh incubation
£asks with 3 ml of identical bu¡er, but containing 0.25 WCi/ml of [U-
14
C]glucose (Amersham International, Amersham, UK) and bovine
insulin (Sigma Chemical Co, Poole, UK) at 0, 10, 50, 100, 1000 and
10 000 WU/ml with recombinate murine leptin dissolved in phosphate
bu¡ered saline (PBS) or an equivalent volume of PBS [12]. The
muscles were then incubated for another 60 min in a shaking water
bath with continuous gassing. At the end of the incubation period,
muscles were removed, trimmed of tendons, blotted and rapidly fro-




C]glucose incorporation into glycogen (glyco-
gen synthesis) was measured following potassium hydroxide digestion
and ethanol precipitation [14] and results are expressed as Wmol glu-
cosyl units/h/g wet weight. The concentration of lactate in the incu-
bation medium was determined spectrophotometrically [14].
2.3. Expression of the full-length leptin receptor (Ob-Rb) mRNA in
soleus muscle
Total RNA was isolated from tissues of lean (+/+) and obese (ob/
ob) mice by the use of RNaid plus kit (BIO 101 Inc., USA). RNA
samples (V4 Wg) were treated with DNAse I for 15 min and then
reverse transcribed, using (dT)
15
Superscript reverse transcriptase II
together with a biological ribonuclease inhibitor (Amersham Int.,
Amersham, UK), according to the manufacturers guidelines (Gib-
coBRL, Life Technol., Paisley, UK). Expression of the full-length
leptin receptor mRNA, Ob-Rb, and the common extracellular domain
mRNA, Ob-R, were established by RT-PCR using domain-speci¢c
primers (Ob-Rb, sense, 5P-TCTTCTGGAGCCTGAACCCATTTC-
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3P, antisense, 5P-TTCTCACCAGAGGTCCCTAAACTC-3P, 30.68
kb; and Ob-R, sense 5P-GGAATGAGCAGGTCAAAAC-3P ; anti-
sense, 5P-GTGACTTCCATATGCAAACC-3P, 30.47 kb). For quan-
titative PCR a shorter fragment of the Ob-Rb was used to relate it
better to the kinetic performances of the Ob-R and L-actin sequences
ampli¢ed. Thus, all cDNA samples were diluted serially (3^5-fold)
then split equally and used either for PCR ampli¢cation of the Ob-
Rb cDNA isoform (37 cycles, using primers; sense, 5P-ACACTGT-
TAATTTCACACCAGAG-3P ; antisense, 5P-TGGATAAACCCTTG-
CTCTTCA-3P 30.45 kb), or all leptin receptor (Ob-R) cDNA iso-
forms (37 cycles, using the primers listed above) and ¢nally the
mouse L-actin cDNA (30 cycles, using Clontech, USA, primers). Pol-
ymerase chain reaction (PCR) ampli¢cation was performed with Am-
pliTaq (Perkin Elmer, UK) in a thermocycler (Techne, Cambrdige,
UK), each cycle as: 95EC 45 s, 55EC 30 s and 72EC 1 min. After
completion (30^37 cycles) the mixture was incubated at 72EC for 10
min. PCR products were either fractionated on agarose gels or spotted
on Hybond N+ membranes (Amersham, UK) and the amount as-
sessed quantitatively by Southern blot hybridization using short di-
goxygenin (DIG-5P) labelled antisense probes. Thus, the Ob-Rb was
detected with DIG5P-GGGCTGGGAATGTGCACAGGATTCCT-
GCCTCACC-3P, and the Ob-R (all isoforms); with DIG5P-
GCGAGTCGGTGGAACGTGGCTGAT-3P, and ¢nally the L-actin
sequence was detected with a commercial probe (Clontech, USA).
Hybridization was in a Rapid-hyb bu¡er (Amersham, UK) and con-
ditions of hybridization and chemiluminescent detection performed as
described previously [12].
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Fig. 3. E¡ects of leptin (100 nM) on glycogen synthesis in soleus
muscle of 6^10-week-old db/db mice (n=8).
Fig. 4. Expression of Ob-R and Ob-Rb mRNAs in soleus muscle of
+/+ and ob/ob mice as determined by RT-PCR and ethidium bro-
mide staining, using primers as described in Section 2. PCR ampli¢-
cation of samples (DNase I-treated) in which the reverse transcrip-
tase was omitted, during cDNA synthesis, resulted in non-detectable
PCR production (data not shown). A 100-bp DNA ladder was used
as a molecular weight marker.
Fig. 1. (a) E¡ects of leptin (100 nM) on glycogen synthesis in soleus
muscle of 8^10 week old ob/ob mice (n=7^9). (b) Dose-dependent
e¡ects of leptin on basal and insulin-stimulated (100 WU/ml) glyco-
gen synthesis in soleus muscle of 8^11-week-old ob/ob mice (n=8^
10). *P6 0.05, 2P6 0.01, leptin-treated versus control (Student's un-
paired t-test).
Fig. 2. E¡ects of leptin (100 nM) on basal and insulin-stimulated
glycogen synthesis in soleus muscle of 8^10-week-old wild-type
(+/+) mice (n=7^10).
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3. Results
Recombinant murine leptin at 100 nM inhibited glycogen
synthesis in soleus muscle of ob/ob mice (Fig. 1a), with 35%
inhibition at basal (P6 0.01), and 28%, 30% and 45% at in-
sulin concentrations (10, 50 and 100 WU/ml, respectively,
P6 0.05) in the physiological range. However, the maximal
response following treatment with insulin (10 000 WU/ml) was
not signi¢cantly a¡ected by leptin (Fig. 1a). The e¡ects of
lower concentrations of leptin (1 and 10 nM) on glycogen
synthesis in the soleus muscle of ob/ob mice were examined
under basal condition and in the presence of 100 WU/ml of
insulin. Leptin at 10 nM caused signi¢cant inhibition of both
basal and insulin-stimulated glycogen synthesis (32% and
35%, respectively; P6 0.05), whereas at 1 nM the inhibition
(13% and 24%) was not signi¢cant (Fig. 1b). These results
demonstrate that the e¡ect of leptin on glycogen synthesis
in muscle from ob/ob mice is dose-dependent (i.e. 13%, 32%
and 35% inhibition respectively of the basal rate and 24%,
35% and 45% inhibition respectively of the 100 WU/ml insu-
lin-stimulated rate, at 1, 10 and 100 nM of leptin, respec-
tively). The rate of lactate formation in the muscle incubation
media of ob/ob mice was not a¡ected by leptin (data not
shown). Also, leptin (100 nM) had no e¡ect on either basal
or insulin-stimulated 2-deoxy-[
3
H]glucose uptake and phos-
phorylation in the soleus muscle of ob/ob mice (percentage
of the paired control values: 95.6þ 9.6% of basal rate;
105.1 þ 5.6% of 1000 WU/ml of insulin-stimulated rate; n=6).
In lean (+/+) mice, there was a trend towards inhibition of
glycogen synthesis by leptin (100 nM), with 20% inhibition at
basal (non-signi¢cant) and 32% inhibition at 100 WU/ml of
insulin (P=0.06; Fig. 2). Studies were also undertaken using
soleus muscles of db/db mice, which lack the functional Ob-Rb
receptor. Leptin (100 nM) did not a¡ect either the basal rate
of glycogen synthesis or the rate in the presence of 50 WU/ml
of insulin (Fig. 3).
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Fig. 5. Expression of Ob-R, Ob-Rb and L-actin mRNA species in soleus muscle of +/+ and ob/ob mice, measured (n=6) by quantitative PCR
ampli¢cation. These are the optimized linear ranges of PCR ampli¢cation of di¡erent cDNAs speci¢ed by hybridization with short DNA
probes. The top left panel shows hybridization blots of PCR products when di¡erent volumes of cDNA from +/+ mice are used, whilst the
other panels show the quantitation of gene expression between the +/+ and ob/ob mouse samples. Data are expressed as þ S.E.M. (n=3), in ar-
bitrary units (A.U.).
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The expression of the Ob-Rb transcript isoform is detected
readily in the soleus muscle by RT-PCR and ethidium bro-
mide staining (Fig. 4). We have also investigated whether
there were any di¡erences in the expression level of the lep-
tin-receptor (Ob-R and Ob-Rb) mRNA in soleus tissues of
wild-type and ob/ob mice, since any di¡erences in receptor
number might indicate variation in the potency of leptin ac-
tion. As the expression of the Ob-Rb transcript is low, quan-
titative PCR was used to determine the relative abundances of
the Ob-Rb mRNA expression in soleus muscle, in a linear
range of PCR conditions [15]. This method resolves changes
in expression that are less than 2-fold. Thus RNA samples
were diluted serially and PCR ampli¢cation performed at a
¢xed number of cycles. L-Actin was used as endogenous con-
trol in a separate reaction to assess loading. When the ratios
of PCR products from the leptin receptor cDNA and the
endogenous actin standard of the wild-type and ob/ob mice
were compared, no di¡erences in abundances were detected
(see Fig. 5).
4. Discussion
The ob gene product leptin has been shown to be a regu-
lator of food intake and energy expenditure and these e¡ects
are mediated through leptin receptors in the hypothalamus [1].
However, leptin receptors have been found also in many pe-
ripheral tissues including lung, ovary, kidney [11,16] and pan-
creatic islets [12] suggesting that leptin might induce a range
of cellular e¡ects in tissues other than brain.
In vivo studies have shown that the administration of leptin
to ob/ob mice results in a depletion in hepatic glycogen con-
tent [13]. Furthermore, leptin impairs the ¢rst steps of the
insulin signalling chain, i.e. auto-phosphorylation of the insu-
lin receptor and tyrosine phosphorylation of insulin receptor
substrate-1 in rat-1 ¢broblasts overexpressing human insulin
receptors, NIH3T3 cells [17] and hep G2 cells [18].
Skeletal muscle is the major site of insulin-mediated glucose
uptake. Furthermore, defective glycogen synthesis in muscle is
one of the earliest manifestations of insulin resistance. Since
insulin resistance is associated with obesity, which has in turn
been associated with increased secretion of leptin, we deter-
mined the direct e¡ect of leptin on basal and insulin-stimu-
lated glycogen synthesis using the isolated soleus muscle prep-
aration. Our results provide the ¢rst evidence that leptin
directly inhibits glycogen synthesis in muscle. This action of
leptin was more marked in muscles from ob/ob mice than in
muscles from lean animals. This latter ¢nding is consistent
with the ¢nding of others that ob/ob mice are more sensitive
to the e¡ects of leptin than lean littermates [4^6]. The reason
for these di¡erences in e¤cacy is not known, but as there were
no detectable di¡erences in the expression level of the Ob-Rb
in soleus muscle of lean and ob/ob mice, it is possible that the
leptin receptor or the post-receptor machinery of ob/ob mice
has increased signalling e¤ciency to exogenous leptin.
In humans, the serum leptin concentration correlates with
percentage body fat [7,8], but insulin resistance has been re-
ported to be associated with elevated plasma leptin levels in-
dependent of body fat mass [19]. Leptin concentrations in
humans are usually in the range 0.1^5 nM [20], whereas in
rodents plasma concentrations up to 20 nM [21] have been
recorded. The concentration of leptin found to be e¡ective in
reducing insulin mediated-glycogen synthesis, in the present
study (10^100 nM), is somewhat higher than that measured
in most human obese subjects. However, such an apparent
discrepancy between exogenous doses of leptin used in vivo
and in vitro in rodents studies and the plasma concentration
in man is a common ¢nding [22,23]. It is possible that re-
combinant leptin does not have the same potency as that
produced endogenously, possibly as a result of post-transla-
tional modi¢cation [22]. Thus the present ¢ndings raise the
possibility that high circulating leptin concentrations in obese
subjects might partially inhibit insulin-mediated muscle glyco-
gen synthesis. Taken together with our earlier ¢nding [12] that
leptin can inhibit glucose-induced and basal insulin secretion,
it is proposed that excessive leptin secretion might potentiate
impaired glucose tolerance in obese subjects.
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